Shereena P. Hydrose

Doha, DA, Qatar

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Crosstalk Between the Oncoproteins of High-Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models.

Crosstalk Between the Oncoproteins of High-Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models.

Journal: Cancer reports (Hoboken, N.J.)

Published: March 19, 2024

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.

Journal: Frontiers in immunology

Published: February 02, 2023

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Journal: Journal of translational medicine

Published: December 22, 2022

The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).

The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).

Journal: European journal of pharmacology

Published: November 29, 2022

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.

Journal: Frontiers in immunology

Published: November 13, 2022

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study.

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study.

Journal: Frontiers in immunology

Published: October 04, 2022

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 23, 2021

Anti-cancer effects of Tranilast: An update.

Anti-cancer effects of Tranilast: An update.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 25, 2021

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.

Journal: Journal for immunotherapy of cancer

Published: August 04, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026